ProteoNic Closes €6m Equity Financing

ProteoNic B.V., a Leiden, the Netherlands-based biotech company, has closed a €6m equity financing.

The round was led by Fairbanks Investment Fund, with participation from existing shareholders.

The company intends to use the funds to accelerate commercialization of its technology and expand its capabilities in the area of cell line generation and contract services.

Led by CEO Frank Pieper, ProteoNic has developed proprietary (UNic™) recombinant protein yield enhancement technology, which is applied in the production of industrial enzymes and biopharmaceutical proteins.



Join the discussion